The NFXF-led patient-focused drug development meeting was held March 3, 2021. The purpose of this meeting was for FDA and other researchers to hear from YOU to help guide future drug development in Fragile X syndrome. We asked patients, family members, caregivers, and patient advocates to share their experiences at this meeting while all other attendees were in listening mode. What you shared can inform FDA’s decisions and oversight both during drug development and during FDA’s review of a marketing application. There will be a final report that summarizes the meeting, helping researchers design more patient-centric and effective treatments.